Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...
Anthera Pharmaceuticals, Inc., a development st...
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
Founded in 1996, PetMed Express is America's Largest Pet Pharmacy, delivering pres...
Founded in 1996, PetMed Express is America's La...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.